Pharma Mutual Funds: Is Your ₹1,000 SIP Worth It?

A new pharma and healthcare mutual fund NFO is open for subscription. Before you invest, here's what sector funds actually mean for your SIP, the risks involved, and whether this fits a middle-class investor's portfolio.

Here's what happened: A major asset management company has launched a new fund focused exclusively on pharma, healthcare, and allied sectors, open for subscription for roughly two weeks.. The fund will invest primarily in listed Indian pharma and healthcare companies — a sector that includes hospitals, diagnostics, API makers, and drug exporters.. This is a thematic/sector fund, meaning SEBI rules require it to keep at least 80% of its corpus in pharma and healthcare stocks with limited flexibility to diversify..

What you should do: Compare this NFO against existing pharma mutual funds with a 3-5 year track record before committing — historical performance beats a ₹10 NAV every time.. Check that pharma/healthcare exposure stays below 10-15% of your total equity portfolio — over-concentration in one sector can devastate returns if the sector underperforms.. Avoid investing your emergency fund or short-term savings (under 5 years) in sector funds — their volatility demands a long horizon of at least 7-10 years..

Pro tip: SEBI allows you to invest in an NFO and redeem after the lock-in without any exit load if you switch to an existing fund from the same AMC within 30 days — check the scheme document for this clause before investing.

For readers weighing their credit and loan options, our personal loan guide and CIBIL score resources put this update in context.